Abbott India Ltd (ABBOTINDIA) — shareholding pattern, promoter holding, financials and share price
About Abbott India Ltd (ABBOTINDIA)
Abbott India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ABBOTINDIA and on the BSE under scrip code 500488. Its ISIN is INE358A01014.
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. [1] It was established in 1944. [2]
Abbott India Ltd is a leading multinational pharmaceutical company with a manufacturing facility in Goa and various third-party manufacturers across India.
It operates in therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health, offering a diverse product portfolio.
Listed peers in Pharmaceuticals: Biocon Ltd, Alkem Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Ipca Laboratories Ltd, Ajanta Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹27,124.95 a share on 10 Jul 2026, Abbott India Ltd (ABBOTINDIA) was valued at a price-to-earnings ratio of 37.14x against an industry P/E of 36.41x and a price-to-book of 13.62x on a book value of ₹1,992.14 per share as of Mar 2025. Solomo computes return on equity of 36.66% and return on capital employed of 47.5% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 37.14x
- Industry P/E
- 36.41x
- P/B
- 13.62x
- EPS (TTM)
- ₹730.39
- Book value / share
- ₹1,992.14
- ROE
- 36.66%
- ROCE
- 47.5%
- ROA
- 26.23%
- Debt / equity
- 0.05x
- Dividend yield
- 1.75%
- EBITDA margin
- 31.46%
- 52-week range
- ₹25,164 – ₹35,280
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Abbott India Ltd (ABBOTINDIA) reported revenue of ₹6,929 crore, net profit of ₹1,552 crore and earnings per share of ₹730.39. That compares with revenue of ₹6,409 crore and net profit of ₹1,414 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,710 crore and net profit ₹395 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 |
| Net profit (₹ cr) | 799 | 949 | 1,201 | 1,414 | 1,552 |
| EPS (₹) | 375.87 | 446.8 | 565.3 | 665.64 | 730.39 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.33% | 9.38% | 9.26% | 14.52% |
| Profit growth | 20.96% | 18.99% | 20.99% | 16.35% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 74.99% of Abbott India Ltd (ABBOTINDIA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.38% and domestic institutional investors (DII) hold 8.78%. Market capitalisation was ₹57,639 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: SBI NIFTY MIDCAP 150 MOMENTUM 50 ETF 1.92%, NIPPON LIFE INDIA TRUSTEE LTD 1.07%, CANARA ROBECO MUTUAL FUND 1.07%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 74.99% | - | 0.38% | 8.78% | 25.01% |
| Mar 2026 | 74.99% | - | 0.26% | 8.93% | 25.01% |
| Dec 2025 | 74.99% | - | 0.18% | 9% | 25.01% |
| Sep 2025 | 74.99% | - | 0.16% | 9.11% | 25.01% |
| Jun 2025 | 74.99% | - | 0.16% | 9.19% | 25.01% |
| Mar 2025 | 74.99% | - | 0.16% | 8.92% | 25.01% |
| Dec 2024 | 74.99% | - | 0.16% | 9.01% | 25.01% |
| Sep 2024 | 74.99% | - | 0.16% | 8.99% | 25.01% |